

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
17 August 2023 (17.08.2023)



(10) International Publication Number
WO 2023/154842 A1

(51) International Patent Classification:

C07D 401/12 (2006.01) A61P 5/14 (2006.01)
A61K 31/506 (2006.01)

(21) International Application Number:

PCT/US2023/062351

(22) International Filing Date:

10 February 2023 (10.02.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/308,709 10 February 2022 (10.02.2022) US
63/419,790 27 October 2022 (27.10.2022) US

(71) Applicant: MADRIGAL PHARMACEUTICALS, INC.

[US/US]; Four Tower Bridge, 200 Barr Harbor Drive, Suite
200, West Conshohocken, Pennsylvania 19428 (US).

(72) Inventors: HENNAN, James K.; 351 Sunnyside Avenue,

Harleysville, Pennsylvania 19438 (US). CONFALONE,
Pasquale N.; 303 Centennial Circle, Wilmington, Delaware
19807 (US).

(74) Agent: ERLACHER, Heidi A. et al.; Cooley LLP, 1299

Pennsylvania Ave., NW, Suite 700, Washington, District of
Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV,

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,
SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: THR BETA ANALOGS AND USES THEREOF

(57) Abstract: Described herein are compounds of formula I: (I), and pharmaceutically acceptable salts, solvates, and stereoisomers thereof, and their uses as thyroid hormone receptor (THR) β activators.



WO 2023/154842 A1